Exacerbations of COPD are common and ... for 7–10 days recommended in current guidelines. Chronic obstructive pulmonary disease (COPD) is a condition of chronic airflow limitation that is ...

The relationship between chronic obstructive pulmonary disease (COPD ... including diagnostic criteria and management of acute exacerbation of CB (AECB) in the elderly patient.

The following is a summary of “Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a ...

Pegtarazimod is under clinical development by ReAlta Life Sciences and currently in Phase I for Coronavirus Disease 2019 (COVID-19) Associated Acute Lung Injury.

Benralizumab is more effective than prednisolone in treating eosinophilic exacerbations in patients with asthma and COPD.

In asthma, lower end-tidal carbon dioxide may predict acute exacerbation outcomes, although other measures may be better severity indicators.

Establish ongoing home care that includes physical, emotional, and spiritual care.

In a report released today, Julian Harrison from BTIG reiterated a Buy rating on Mereo Biopharma Group Plc (MREO – Research Report), with a ...

Analyst Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on Mereo Biopharma Group Plc (MREO – Research Report) and keeping the ...

Exceeds the Upper End of Guidance Range for Full-Year 2024 with Unaudited Global Revenues of Approximately $363.7 Million-- --2025 Global ARIKAYCE Revenues Expected to be Between $405 Million ...